Novartis

News

Novartis sheds MorphoSys staff, sites after pelabresib delay

Novartis has confirmed it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, by the end of next year.

News

ICER identifies new crop of 'unsupported' drug price rises

Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.

Oncology

Can CAR-T first movers keep pace in a rapidly evolving marke...

The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market.

News

Novartis bid to block generic Entresto in US suffers setback

An appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic of its heart failure blockbuster Entresto.

News

Woman pushing man in wheelchair along beachfront as sun sets

Novartis pays $1bn upfront for Huntington's drug from PTC

Novartis has made a return to the Huntington's disease stage by licensing an oral mRNA splicer from PTC Therapeutics for $1 billion upfront.

News

Kisqali gets early breast cancer approval in Europe

Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours

Novartis sheds MorphoSys staff, sites after pelabresib delay

ICER identifies new crop of 'unsupported' drug price rises

Can CAR-T first movers keep pace in a rapidly evolving marke...

Novartis bid to block generic Entresto in US suffers setback

Novartis pays $1bn upfront for Huntington's drug from PTC

Kisqali gets early breast cancer approval in Europe

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Novartis

Editor's Picks